Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Type 1 diabetes (T1D) is an autoimmune disease in which the insulin-producing β cells of the pancreas are destroyed by T lymphocytes. Recent studies have demonstrated that monitoring for pancreatic islet autoantibodies, combined with genetic risk assessment, can identify most children who will develop T1D when they still have sufficient β cell function to control glucose concentrations without the need for insulin. In addition, there has been recent success in secondary prevention using immunotherapy to delay the progression of preclinical disease, and primary prevention approaches to inhibiting the initiating autoimmune process have entered large-scale clinical trials. By changing the focus of T1D management from late diagnosis and insulin replacement to early diagnosis and β cell preservation, we can anticipate a future without the need for daily insulin injections for children with T1D.

Original publication

DOI

10.1126/science.abi4742

Type

Journal article

Journal

Science

Publication Date

30/07/2021

Volume

373

Pages

506 - 510

Keywords

Autoantibodies, Biomarkers, Child, Diabetes Mellitus, Type 1, Disease Progression, Early Diagnosis, Genetic Predisposition to Disease, Genetic Testing, Humans, Insulin, Insulin-Secreting Cells, Islets of Langerhans, Primary Prevention, Secondary Prevention